Llwytho...
A Phase II Study of Two Dose Levels of Ofatumumab Induction followed by Maintenance Therapy in Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Despite the recent advances in treatment of CLL with targeted agents such as ibrutinib, availability of non-chemotherapy based therapies is desired. Given the 58% response rate (1996 NCI-WG criteria) of single agent ofatumumab in CLL refractory to fludarabine and alemtuzumab, we initiated a phase II...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Am J Hematol |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5500306/ https://ncbi.nlm.nih.gov/pubmed/27387131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24468 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|